- Previous Close
1.5800 - Open
1.5800 - Bid --
- Ask --
- Day's Range
1.4500 - 1.5900 - 52 Week Range
1.4500 - 6.2650 - Volume
22,470 - Avg. Volume
42,224 - Market Cap (intraday)
19.953M - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2200 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
www.calcimedica.comRecent News: CALC
View MorePerformance Overview: CALC
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CALC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CALC
View MoreValuation Measures
Market Cap
21.30M
Enterprise Value
2.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.48
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-94.61%
Return on Equity (ttm)
-121.42%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.7M
Diluted EPS (ttm)
-1.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
18.67M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-13.74M